Archives of Toxicology

, Volume 87, Issue 1, pp 111–122 | Cite as

The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines?

  • Diana Dias da Silva
  • Helena Carmo
  • Elisabete Silva
Toxicokinetics and Metabolism

Abstract

The recreational and illicit use of amphetaminic designer compounds, specially 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy), is of concern worldwide. Such psychostimulating drugs are frequently present as complex mixtures in ‘rave’ pills, making concomitant polysubstance use a common trend. However, the understanding of possible combination effects with these substances is still scarce. The present study was aimed at predicting the cytotoxic effects of mixtures of four amphetaminic derivatives: MDMA, methamphetamine, 4-methylthioamphetamine and d-amphetamine in a human hepatoma cell line. Concentration–response curves for all single-mixture components were recorded by the MTT assay. Data obtained for individual agents were then used to compute the additivity expectations for mixtures of definite composition, using the pharmacological models of concentration addition (CA) and independent action. By comparing the predicted calculations with the experimentally observed effects, we concluded that CA accurately predicts the combination of amphetamines, which act together to generate additive effects over a large range of concentrations. Notably, we observed substantial mixture effects even when each drug was present at low concentrations, which individually produced unnoticeable effects. Nonetheless, for all tested mixtures, a small deviation from additivity was observed towards higher concentrations, particularly at high effect levels. A possible metabolic interaction, which could explain such deviation, was investigated, and it was observed that at higher mixture concentrations increased MDMA metabolism could be contributing to divergences from additivity. In conclusion, the present work clearly demonstrates that potentially harmful interactions among amphetaminic drugs are expected when these drugs are taken concomitantly.

Keywords

3,4-methylenedioxymethamphetamine (ecstasy, MDMA) Amphetamine-related toxicity Hepatocytes Combination effects Concentration addition (CA) Independent action (IA) 

References

  1. Altenburger R, Backhaus T, Boedeker W, Faust M, Scholze M, Grimme LH (2000) Predictability of the toxicity of multiple chemical mixtures to Vibrio fisheri: mixtures composed of similarly acting chemicals. Environ Toxicol Chem 19(9):2341–2347Google Scholar
  2. Backhaus T, Altenburger R, Boedeker W, Faust M, Scholze M, Grimme LH (2000a) Predictability of the toxicity of a multiple mixture of dissimilarly acting chemicals to Vibrio fischeri. Environ Toxicol Chem 19(9):2348–2356Google Scholar
  3. Backhaus T, Scholze M, Grimme LH (2000b) The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. Aquat Toxicol 49(1–2):49–61PubMedCrossRefGoogle Scholar
  4. Barbosa DJ, Capela JP, Oliveira JM et al (2012) Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes. Br J Pharmacol 165(4b):1017–1033. doi:10.1111/j.1476-5381.2011.01453.x PubMedCrossRefGoogle Scholar
  5. Barrett SP, Darredeau C, Pihl RO (2006) Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol Clin 21(4):255–263. doi:10.1002/Hup.766 CrossRefGoogle Scholar
  6. Becker J, Neis P, Rohrich J, Zorntlein S (2003) A fatal paramethoxymethamphetamine intoxication. Leg Med (Tokyo) 5(Suppl 1):S138–S141CrossRefGoogle Scholar
  7. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585–615CrossRefGoogle Scholar
  8. Camilleri AM, Caldicott D (2005) Underground pill testing, down under. Forensic Sci Int 151(1):53–58. doi:10.1016/J.Forsciint.2004.07.004 PubMedCrossRefGoogle Scholar
  9. Capela JP, Meisel A, Abreu AR et al (2006) Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J Pharmacol Exp Ther 316(1):53–61. doi:10.1124/jpet.105.092577 PubMedCrossRefGoogle Scholar
  10. Carmo H, Hengstler JG, de Boer D et al (2004) Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch Pharmacol 369(2):198–205. doi:10.1007/S00210-003-0850-0 PubMedCrossRefGoogle Scholar
  11. Carvalho M, Hawksworth G, Milhazes N et al (2002) Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 76(10):581–588. doi:10.1007/S00204-002-0381-3 PubMedCrossRefGoogle Scholar
  12. Carvalho M, Remiao F, Milhazes N et al (2004a) The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 200(2–3):193–203. doi:10.1016/j.tox.2004.03.016 PubMedCrossRefGoogle Scholar
  13. Carvalho M, Remiao F, Milhazes N et al (2004b) Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 17(5):623–632. doi:10.1021/tx049960f PubMedCrossRefGoogle Scholar
  14. Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F (2010) Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol 11(5):476–495PubMedCrossRefGoogle Scholar
  15. Carvalho M, Carmo H, Costa VM et al (2012) Toxicity of amphetamines: an update. Arch Toxicol. doi:10.1007/s00204-012-0815-5 Google Scholar
  16. Chen Q, Cederbaum AI (1997) Menadione cytotoxicity to Hep G2 cells and protection by activation of nuclear factor-kappaB. Mol Pharmacol 52(4):648–657PubMedGoogle Scholar
  17. Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS (2005) MDMA (‘Ecstasy’) and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49(2):195–207. doi:10.1016/j.neuropharm.2005.03.002 PubMedCrossRefGoogle Scholar
  18. Cloonan SM, Keating JJ, Corrigan D et al (2010) Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines. Bioorg Med Chem 18(11):4009–4031. doi:10.1016/J.Bmc.2010.04.022 PubMedCrossRefGoogle Scholar
  19. Custodio JBA, Santos MS, Goncalves DIR et al (2010) Comparative effects of 3,4-methylenedioxymethamphetamine and 4-methylthioamphetamine on rat liver mitochondrial function. Toxicology 270(2–3):99–105. doi:10.1016/J.Tox.2010.01.022 PubMedCrossRefGoogle Scholar
  20. da Silva DG, de Pinho PG, Pontes H et al (2010) Gas chromatography-ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine. J Chromatogr, B: Anal Technol Biomed Life Sci 878(9–10):815–822. doi:10.1016/j.jchromb.2010.01.042 Google Scholar
  21. Darroudi F, Meijers CM, Hadjidekova V, Natarajan AT (1996) Detection of aneugenic and clastogenic potential of X-rays, directly and indirectly acting chemicals in human hepatoma (Hep G2) and peripheral blood lymphocytes, using the micronucleus assay and fluorescent in situ hybridization with a DNA centromeric probe. Mutagenesis 11(5):425–433PubMedCrossRefGoogle Scholar
  22. de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances—monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 43(3):157–185PubMedCrossRefGoogle Scholar
  23. De Letter EA, Coopman VAE, Cordonnier JACM, Piette MHA (2001) One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int J Legal Med 114(6):352–356PubMedCrossRefGoogle Scholar
  24. De Letter EA, Bouche MP, Van Bocxlaer JF, Lambert WE, Piette MH (2004) Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int 141(2–3):85–90. doi:10.1016/j.forsciint.2003.12.015 PubMedCrossRefGoogle Scholar
  25. De Letter EA, Piette MHA, Lambert WE, Cordonnier JACM (2006) Amphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976–2004. Med Sci Law 46(1):37–65PubMedCrossRefGoogle Scholar
  26. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9(1):1–11PubMedCrossRefGoogle Scholar
  27. Doostdar H, Grant MH, Melvin WT, Wolf CR, Burke MD (1993) The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol 46(4):629–635PubMedCrossRefGoogle Scholar
  28. Drescher K, Boedeker W (1995) Assessment of the combined effects of substances—the relationship between concentration addition and independent action. Biometrics 51(2):716–730CrossRefGoogle Scholar
  29. Elliott SP (2000) Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). J Anal Toxicol 24(2):85–89PubMedGoogle Scholar
  30. Garcia-Repetto R, Moreno E, Soriano T, Jurado C, Gimenez MP, Menendez M (2003) Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 135(2):110–114. doi:10.1016/S0379-0738(03)00179-8 PubMedCrossRefGoogle Scholar
  31. Hayat S, Williams RJ, Rattray M (2006) Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro. J Psychopharmacol 20(2):257–263. doi:10.1177/0269881106063273 PubMedCrossRefGoogle Scholar
  32. Jimenez A, Jorda EG, Verdaguer E et al (2004) Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol Appl Pharm 196(2):223–234. doi:10.1016/J.Taap.2003.12.017 CrossRefGoogle Scholar
  33. Jones AL, Simpson KJ (1999) Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 13(2):129–133PubMedCrossRefGoogle Scholar
  34. Knasmuller S, Mersch-Sundermann V, Kevekordes S et al (2004) Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198(1–3):315–328. doi:10.1016/j.tox.2004.02.008 PubMedCrossRefGoogle Scholar
  35. Loewe S, Muchnik H (1926) Effect of combinations: mathematical basis of the problem. Arch Exp Pathol Pharmakol 114:313–326CrossRefGoogle Scholar
  36. Milroy CM (1999) Ten years of ‘ecstasy’. J R Soc Med 92(2):68–72PubMedGoogle Scholar
  37. Milroy CM, Clark JC, Forrest AR (1996) Pathology of deaths associated with “ecstasy” and “eve” misuse. J Clin Pathol 49(2):149–153PubMedCrossRefGoogle Scholar
  38. Mohamed WMY, Ben Hamida S, Cassel JC, de Vasconcelos AP, Jones BC (2011) MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav 99(4):759–774. doi:10.1016/J.Pbb.2011.06.032 PubMedCrossRefGoogle Scholar
  39. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ (2011) Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users. Addiction 106(7):1293–1300. doi:10.1111/J.1360-0443.2011.03399.X PubMedCrossRefGoogle Scholar
  40. Pavlaki MD, Pereira R, Loureiro S, Soares AMVM (2011) Effects of binary mixtures on the life traits of Daphnia magna. Ecotoxicol Environ Saf 74(1):99–110. doi:10.1016/J.Ecoenv.2010.07.010 PubMedCrossRefGoogle Scholar
  41. Pavlic M, Schubert B, Libiseller K, Oberacher H (2010) Comprehensive identification of active compounds in tablets by flow-injection data-dependent tandem mass spectrometry combined with library search. Forensic Sci Int 197(1–3):40–47. doi:10.1016/J.Forsciint.2009.12.019 PubMedCrossRefGoogle Scholar
  42. Payne J, Rajapakse N, Wilkins M, Kortenkamp A (2000) Prediction and assessment of the effects of mixtures of four xenoestrogens. Environ Health Perspect 108(10):983–987PubMedCrossRefGoogle Scholar
  43. Pontes H, Sousa C, Silva R et al (2008) Synergistic toxicity of ethanol and MDMA towards primary cultured rat hepatocytes. Toxicology 254(1–2):42–50. doi:10.1016/j.tox.2008.09.009 PubMedCrossRefGoogle Scholar
  44. Pontes H, de Pinho PG, Fernandes E et al (2010) Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes. Toxicology 270(2–3):150–157. doi:10.1016/J.Tox.2010.02.010 PubMedCrossRefGoogle Scholar
  45. Rajapakse N, Ong D, Kortenkamp A (2001) Defining the impact of weakly estrogenic chemicals on the action of steroidal estrogens. Toxicol Sci Off J Soc Toxicol 60(2):296–304Google Scholar
  46. Rajapakse N, Silva E, Kortenkamp A (2002) Combining xenoestrogens at levels below individual No-observed-effect concentrations dramatically enhances steroid hormone action. Environ Health Perspect 110(9):917–921PubMedCrossRefGoogle Scholar
  47. Ripp SL, Falkner KC, Pendleton ML, Tamasi V, Prough RA (2003) Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene. Mol Pharmacol 64(1):113–122. doi:10.1124/mol.64.1.113 PubMedCrossRefGoogle Scholar
  48. Scholze M, Boedeker W, Faust M, Backhaus T, Altenburger R, Grimme LH (2001) A general best-fit method for concentration-response curves and the estimation of low-effect concentrations. Environ Toxicol Chem 20(2):448–457PubMedGoogle Scholar
  49. Shenouda SK, Varner KJ, Carvalho F, Lucchesi PA (2009) Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. Cardiovasc Toxicol 9(1):30–38. doi:10.1007/S12012-009-9034-6 PubMedCrossRefGoogle Scholar
  50. Sherlock K, Wolff K, Hay AWM, Conner M (1999) Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med 16(3):194–197PubMedCrossRefGoogle Scholar
  51. Silva E, Rajapakse N, Kortenkamp A (2002) Something from “nothing”—eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environ Sci Technol 36(8):1751–1756. doi:10.1021/Es0101227 PubMedCrossRefGoogle Scholar
  52. Silva E, Rajapakse N, Scholze M, Backhaus T, Ermler S, Kortenkamp A (2011a) Joint effects of heterogeneous estrogenic chemicals in the E-screen-exploring the applicability of concentration addition. Toxicol Sci 122(2):383–394. doi:10.1093/Toxsci/Kfr103 PubMedCrossRefGoogle Scholar
  53. Silva R, Carmo H, Dinis-Oliveira R et al (2011b) In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 85(4):315–326. doi:10.1007/S00204-010-0587-8 PubMedCrossRefGoogle Scholar
  54. Simantov R, Tauber M (1997) The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J Off Publ Fed Am Soc Exp Biol 11(2):141–146Google Scholar
  55. Stumm G, Schlegel J, Schafer T et al (1999a) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J Off Publ Fed Am Soc Exp Biol 13(9):1065–1072Google Scholar
  56. Stumm G, Schlegel J, Schafer T et al (1999b) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J 13(9):1065–1072PubMedGoogle Scholar
  57. Tang RX, Kong FY, Fan BF et al (2012) HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module. World J Gastroenterol 18(13):1485–1495. doi:10.3748/Wjg.V18.I13.1485 PubMedCrossRefGoogle Scholar
  58. Tanner-Smith EE (2006) Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. Drug Alcohol Depend 83(3):247–254. doi:10.1016/J.Drugalcdep.2005.11.016 PubMedCrossRefGoogle Scholar
  59. Teng SF, Wu SC, Liu CR, Li JH, Chien CS (2006) Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci Int 161(2–3):202–208. doi:10.1016/J.Forsciint.2006.03.035 PubMedCrossRefGoogle Scholar
  60. Verschraagen M, Maes A, Ruiter B, Bosman IJ, Smink BE, Lusthof KJ (2007) Post-mortem cases involving amphetamine-based drugs in the Netherlands—comparison with driving under the influence cases. Forensic Sci Int 170(2–3):163–170. doi:10.1016/J.Forsciint.2007.03.030 PubMedCrossRefGoogle Scholar
  61. Walubo A, Seger D (1999) Fatal multi-organ failure after suicidal overdose with MDMA, ‘Ecstasy’: case report and review of the literature. Hum Exp Toxicol 18(2):119–125PubMedCrossRefGoogle Scholar
  62. Wu LT, Schlenger WE, Galvin DM (2006) Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 84(1):102–113. doi:10.1016/J.Drugalcdep.2006.01.002 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Diana Dias da Silva
    • 1
    • 2
    • 3
    • 4
  • Helena Carmo
    • 3
  • Elisabete Silva
    • 4
  1. 1.Faculdade de MedicinaUniversidade do PortoPortoPortugal
  2. 2.UCL School of PharmacyUniversity College LondonLondonUK
  3. 3.REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
  4. 4.Institute for the EnvironmentBrunel UniversityKingston Lane, Uxbridge, MiddlesexUK

Personalised recommendations